The dual effectiveness creates a clear path for both immediate warrant-share resale and future shelf takedowns. With a $9M market cap, even modest selling from the resale registration could pressure the stock. Monitor for any 424B prospectus filings indicating an underwritten offering or direct shelf takedown, which would confirm near-term dilution.
Price Chart
Executive Summary
IceCure Medical received two EFFECT notices on August 18, 2026, making registration statements 333-288062 and 333-294827 effective. Filing 333-288062 relates to a resale registration for up to 16 million shares underlying Series B and C warrants from a March 2026 offering, while 333-294827 is a separate shelf registration. The dual effectiveness, amplified by the cross-filing actuarial verdict, signals that the company now has both immediate resale capacity for existing warrant shares and a fresh shelf for future capital raising, creating a persistent dilution overhang for a $9M market cap stock.
Key Facts
- Two EFFECT notices declared effective on 2026-08-18 for file numbers 333-288062 and 333-294827.
- 333-288062 covers resale of up to 16 million shares issuable upon exercise of Series B and C warrants from a March 2026 offering.
- 333-294827 is a separate shelf registration statement (type POS AM) that went effective on the same day.
- The company will not receive proceeds from the resale registration but could receive $8.8 million if all warrants are exercised.
- Market cap is approximately $9M, making the potential dilution from 16M+ shares highly material.
- Cross-filing actuarial verdict confirms an AMPLIFIER effect for IPO + shelf context, supporting elevated impact.
Financial Impact
Up to 16 million shares eligible for resale from warrant exercises, plus an additional shelf registration for future offerings — highly dilutive relative to a ~$9M market cap.
Risk Factors
- Immediate overhang from up to 16M resale shares hitting the market.
- Additional dilution from the newly effective shelf registration (333-294827) for future capital raises.
- Low market cap ($9M) amplifies the impact of any share issuance or resale.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (ICCM) — Batch item 1 | 9999999995-26-002689 |
| Document: 9999999995-26-002689-index.html | 9999999995-26-002690 |
| Document: 9999999995-26-002689.txt | 9999999995-26-002689 |
| EFFECT Filing (ICCM) — Batch item 4 | 9999999995-26-002690 |
| Document: 9999999995-26-002690-index.html | 9999999995-26-002689 |
| Document: 9999999995-26-002690.txt | 9999999995-26-002689 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 6-K | $1.10 | awaiting T+60 | — | $1.03 (−6.36%) |
Oct 5, 2026 21d ago | 6-K | $1.27 | awaiting T+60 | — | $1.03 (−18.90%) |
Oct 5, 2026 21d ago | 6-K | $1.54 | awaiting T+60 | — | $1.03 (+33.12%) |
Sep 10, 2026 6w ago | 6-K | $2.14 | awaiting T+60 | — | $1.03 (−51.87%) |
Aug 24, 2026 9w ago | 6-K | $2.27 | awaiting T+60 | — | $1.03 (−54.63%) |
Aug 19, 2026 9w ago | EFFECT | $2.52 | awaiting T+60 | — | $1.03 (+59.13%) |
Aug 14, 2026 10w ago | 6-K | $2.82 | awaiting T+60 | — | $1.03 (−63.48%) |
Aug 12, 2026 10w ago | 6-K | $3.11 | awaiting T+60 | — | $1.03 (−66.83%) |
Jul 6, 2026 16w ago | EFFECT | $4.61 $1.59 | ▲ +65.51% | ▲ +67.23% | $1.03 (+77.66%) |
Jun 26, 2026 17w ago | 6-K | $5.26 $1.95 | ▲ +62.93% | ▲ +67.31% | $1.03 (+80.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers